冠心病介入治疗相关造影剂肾病防治的研究进展  

Advances in Research on Prevention and Treatment of Contrast-medium Nephropathy Related to Interventional Therapy of Coronary Heart Disease

作　　者：林晓强[1] 吴志福[1] 王纲[1] 詹源胜[1] LIN Xiaoqiang;WU Zhifu;WANG Gang;ZHAN Yuansheng(Department of Cardiology,Beihai People's Hospital,Beihai,Guangxi Zhuang Autonomous Region,536000 China)

机构地区：[1]广西北海市人民医院心内科,广西北海536000

出　　处：《中外医疗》2021年第20期194-198,共5页China & Foreign Medical Treatment

基　　金：北海市科技计划项目申报书(北科合201995051)。

摘　　要：造影剂肾病是冠心病介入治疗期间一种较少见的并发症,在多数情况下可逆,但如果未能得到及时、有效的治疗,那么会使肾脏损伤加重,而且还会增加心血管不良事件的发生概率。所以,需迫切采取可行措施,对造影剂急性肾损伤的发生加以预防,减少高危患者不良事件的发生。该文分别从诱发造影剂肾病的主要因素、病理生理机制及具体的防治方法等方面,对冠心病介入治疗的当前研究进展进行剖析,望能为此领域研究有所借鉴。Contrast nephropathy is a rare complication during interventional treatment of coronary heart disease.It is reversible in most cases.However,if it is not treated in time and effective,it will aggravate kidney damage and increase the cardiovascular system.The probability of adverse events.Therefore,feasible measures need to be taken urgently to prevent the occurrence of acute kidney injury from contrast agents and reduce the occurrence of adverse events in high-risk patients.This article analyzes the current research progress of interventional treatment of coronary heart disease from the main factors,pathophysiological mechanisms and specific prevention and treatment methods of inducing contrast-induced nephropathy,and hopes that it can be used as a reference for the research in this field.

关 键 词：冠心病 造影剂肾病 介入治疗 防治进展 

分 类 号：R4[医药卫生—临床医学]